A Constrained Standard Model from a Compact Extra Dimension

A SU(3) \times SU(2) \times U(1) supersymmetric theory is constructed with a TeV sized extra dimension compactified on the orbifold S^1/(Z_2 \times Z_2'). The compactification breaks supersymmetry leaving a set of zero modes which correspond precisely to the states of the 1 Higgs doublet standard model. Supersymmetric Yukawa interactions are localized at orbifold fixed points. The top quark hypermultiplet radiatively triggers electroweak symmetry breaking, yielding a Higgs potential which is finite and exponentially insensitive to physics above the compactification scale. This potential depends on only a single free parameter, the compactification scale, yielding a Higgs mass prediction of 127 \pm 8 GeV. The masses of the all superpartners, and the Kaluza-Klein excitations are also predicted. The lightest supersymmetric particle is a top squark of mass 197 \pm 20 GeV. The top Kaluza-Klein tower leads to the \rho parameter having quadratic sensitivity to unknown physics in the ultraviolet.Comment: 31 pages, Latex, 2 eps figures, minor correction

Clostridium difficile sortase recognizes a (S/P)PXTG sequence motif and can accommodate diaminopimelic acid as a substrate for transpeptidation

AbstractCovalent attachment of surface proteins to the cell wall of Gram-positive bacteria requires a sortase-mediated transpeptidation reaction. In almost all Gram-positive bacteria, the housekeeping sortase, sortase A, recognizes the canonical recognition sequence LPXTG (X=any amino acid). The human pathogen Clostridium difficile carries a single putative sortase gene (cd2718) but neither transpeptidation activity nor specificity of CD2718 has been investigated. We produced recombinant CD2718 and examined its transpeptidation activity in vitro using synthetic peptides and MALDI-ToF(-ToF) MS analysis. We demonstrate that CD2718 has sortase activity with specificity for a (S/P)PXTG motif and can accommodate diaminopimelic acid as a substrate for transpeptidation

Production and Decay of Scalar Stoponium Bound States

In this paper we discuss possible signatures for the production of scalar \stst\ (stoponium) bound states \sigst\ at hadron colliders, where \st\ is the lighter scalar top eigenstate. We first study the decay of \sigst; explicit expressions are given for all potentially important decay modes. If \st\ has unsuppressed two--body decays, they will always overwhelm the annihilation decays of \sigst. Among the latter, we find that usually either the $gg$ or $hh$ final state dominates, depending on the size of the off--diagonal entry of the stop mass matrix; $h$ is the lighter neutral scalar Higgs boson of the minimal supersymmetric model. If \msig\ happens to be close to the mass of one of the neutral scalar Higgs bosons, $Q \bar{Q}$ final states dominate ($Q=b$ or $t$). \ww\ and $ZZ$ final states are subdominant. We argue that \sigst \rightarrow \gamgam decays offer the best signal for stoponium production at hadron colliders. The tevatron should be able to close the light stop window left open by LEP searches, but its mass reach is limited to \msig \leq 90 GeV. In contrast, at the LHC one should ultimately be able to probe the region \msig \leq 700 GeV, if the $hh$ partial width is not too large. We also comment on the feasibility of searching for \sigst\ production at hadron colliders in the $ZZ, \ Z \gamma$ and \fourtau\ final states, and briefly mention \sigst\ production at \gamgam\ colliders.Comment: 31 pages plus 10 figures (available from DREES@WISCPHEN); LaTeX with equation.sty; MAD/PH/808, KEK-TH-37

Probing Supergravity Grand Unification in the Brookhaven g-2 Experiment

A quantitative analysis of \amu\equiv{1\over 2}(g-2)_\mu within the framework of Supergravity Grand Unification and radiative breaking of the electro-weak symmetry is given. It is found that $a_{\mu}^{SUSY}$ is dominated by the chiral interference term from the light chargino exchange, and that this term carries a signature which correlates strongly with the sign of $\mu$. Thus as a rule $a_{\mu}^{SUSY}>0$ for $\mu>0$ and $a_{\mu}^{SUSY}<0$ for $\mu<0$ with very few exceptions when tan$\beta\sim 1$. At the quantitative level it is shown that if the E821 BNL experiment can reach the expected sensitivity of $4\times 10^{-10}$ and there is a reduction in the hadronic error by a factor of four or more, then the experiment will explore a majority of the parameter space in $m_0-m_{\tilde g}$ plane in the region m_0\lsim 400 GeV, m_{\tilde g}\lsim 700 GeV for \tanbeta \gsim 10 assuming the experiment will not discard the Standard Model result within its $2\sigma$ uncertainty limit. For smaller \tanbeta, the SUSY reach of E821 will still be considerable. Further, if no effect within $2 \sigma$ limit of the Standard Model value is seen, then large \tanbeta scenarios will be severely constrained within the current naturalness criterion, ie., m_0, m_{\tilde g}\lsim 1 TeV.Comment: 27 pages, Latex, uuencoded figure file to be obtained and processed separately for two figures. Figures may also be sent on request by mai

Resolving the Constrained Minimal and Next-to-Minimal Supersymmetric Standard Models

We perform a detailed analysis of the next-to-minimal supersymmetric standard model (NMSSM), imposing the constraints of two-loop gauge coupling unification, universal soft supersymmetry breaking and the correct pattern of electroweak symmetry breaking. We compare our results with those for the minimal supersymmetric standard model (MSSM) using closely related techniques and, as far as possible, a common set of input and output variables. In general, in the constrained NMSSM, there are much stronger correlations between parameters than in the constrained MSSM, and we map out the allowed parameter space. We also give a detailed discussion of how to resolve the two models experimentally, concentrating primarily on the prospects at LEPII.Comment: 76 pages, latex, no macros, uuencoded figures included separately. This version (to appear in Phys. Rev. D) contains various minor change

Difficult tracheal intubation in neonates and infants. NEonate and Children audiT of Anaesthesia pRactice IN Europe (NECTARINE): a prospective European multicentre observational study

Background: Neonates and infants are susceptible to hypoxaemia in the perioperative period. The aim of this study was to analyse interventions related to anaesthesia tracheal intubations in this European cohort and identify their clinical consequences. Methods: We performed a secondary analysis of tracheal intubations of the European multicentre observational trial (NEonate and Children audiT of Anaesthesia pRactice IN Europe [NECTARINE]) in neonates and small infants with difficult tracheal intubation. The primary endpoint was the incidence of difficult intubation and the related complications. The secondary endpoints were the risk factors for severe hypoxaemia attributed to difficult airway management, and 30 and 90 day outcomes. Results: Tracheal intubation was planned in 4683 procedures. Difficult tracheal intubation, defined as two failed attempts of direct laryngoscopy, occurred in 266 children (271 procedures) with an incidence (95% confidence interval [CI]) of 5.8% (95% CI, 5.1e6.5). Bradycardia occurred in 8% of the cases with difficult intubation, whereas a significant decrease in oxygen saturation (SpO2&lt;90% for 60 s) was reported in 40%. No associated risk factors could be identified among comorbidities, surgical, or anaesthesia management. Using propensity scoring to adjust for confounders, difficult anaesthesia tracheal intubation did not lead to an increase in 30 and 90 day morbidity or mortality. Conclusions: The results of the present study demonstrate a high incidence of difficult tracheal intubation in children less than 60 weeks post-conceptual age commonly resulting in severe hypoxaemia. Reassuringly, the morbidity and mortality at 30 and 90 days was not increased by the occurrence of a difficult intubation event. Clinical trial registration: NCT02350348

Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.

PURPOSE: As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19-free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS: This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19-free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS: Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19-free surgical pathways. Patients who underwent surgery within COVID-19-free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19-free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score-matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19-free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION: Within available resources, dedicated COVID-19-free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Elective cancer surgery in COVID-19-free surgical pathways during the SARS-CoV-2 pandemic: An international, multicenter, comparative cohort study

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a COVID-19–free surgical pathway (complete segregation of the operating theater, critical care, and inpatient ward areas) or no defined pathway (incomplete or no segregation, areas shared with patients with COVID-19). The primary outcome was 30-day postoperative pulmonary complications (pneumonia, acute respiratory distress syndrome, unexpected ventilation). RESULTS Of 9,171 patients from 447 hospitals in 55 countries, 2,481 were operated on in COVID-19–free surgical pathways. Patients who underwent surgery within COVID-19–free surgical pathways were younger with fewer comorbidities than those in hospitals with no defined pathway but with similar proportions of major surgery. After adjustment, pulmonary complication rates were lower with COVID-19–free surgical pathways (2.2% v 4.9%; adjusted odds ratio [aOR], 0.62; 95% CI, 0.44 to 0.86). This was consistent in sensitivity analyses for low-risk patients (American Society of Anesthesiologists grade 1/2), propensity score–matched models, and patients with negative SARS-CoV-2 preoperative tests. The postoperative SARS-CoV-2 infection rate was also lower in COVID-19–free surgical pathways (2.1% v 3.6%; aOR, 0.53; 95% CI, 0.36 to 0.76). CONCLUSION Within available resources, dedicated COVID-19–free surgical pathways should be established to provide safe elective cancer surgery during current and before future SARS-CoV-2 outbreaks

Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC

DUNE is a dual-site experiment for long-baseline neutrino oscillation studies, neutrino astrophysics and nucleon decay searches. ProtoDUNE Dual Phase (DP) is a 6  ×  6  ×  6 m 3 liquid argon time-projection-chamber (LArTPC) that recorded cosmic-muon data at the CERN Neutrino Platform in 2019-2020 as a prototype of the DUNE Far Detector. Charged particles propagating through the LArTPC produce ionization and scintillation light. The scintillation light signal in these detectors can provide the trigger for non-beam events. In addition, it adds precise timing capabilities and improves the calorimetry measurements. In ProtoDUNE-DP, scintillation and electroluminescence light produced by cosmic muons in the LArTPC is collected by photomultiplier tubes placed up to 7 m away from the ionizing track. In this paper, the ProtoDUNE-DP photon detection system performance is evaluated with a particular focus on the different wavelength shifters, such as PEN and TPB, and the use of Xe-doped LAr, considering its future use in giant LArTPCs. The scintillation light production and propagation processes are analyzed and a comparison of simulation to data is performed, improving understanding of the liquid argon properties